

ASTRAZENECA PLC  
Form 6-K  
December 18, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of December 2015

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

## DURVALUMAB ATLANTIC TRIAL SUPPORTS CLINICAL ACTIVITY AND ASTRAZENECA'S OVERALL IMMUNO-ONCOLOGY STRATEGY

Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage NSCLC patients; full data to be presented at a scientific congress in 2016

Durvalumab monotherapy and combination trials on track in multiple cancers, including 1st-line therapy for NSCLC, head & neck and bladder cancers

AstraZeneca today provided an update on preliminary findings from the ATLANTIC trial of durvalumab as 3rd-line or later stage therapy in patients with locally advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK alterations. An initial analysis supports durvalumab's clinical activity, with durable responses and an established safety profile in these difficult-to-treat patients.

ATLANTIC investigated the efficacy and tolerability of durvalumab in patients who received at least two prior systemic treatment regimens including platinum-based chemotherapy, and who have limited options for further therapy. A full evaluation of the data is ongoing and the results will be presented at a scientific congress in 2016.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "As we have seen in other studies, durvalumab has demonstrated expected clinical activity and durable response in these heavily pre-treated patients. As previously communicated, the treatment and regulatory landscape in lung cancer is evolving. We now believe it is unlikely that ATLANTIC can be used for regulatory submission as a monotherapy, but we will make that determination following a full analysis of the data. Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast advancing development programme focused primarily on novel combinations."

A comprehensive durvalumab registration programme is underway across multiple tumour types, stages of disease, and lines of therapy both as monotherapy and in combination. This forms part of AstraZeneca's late-stage immuno-oncology programme and includes more than 9,000 patients in 16 clinical trials in lung, bladder, head & neck, and other cancers, summarised below.

### DURVALUMAB DEVELOPMENT PROGRAMME

Status as of Year-To-Date and Q3 2015 Financial results on 5 November 2015

Next update with FY 2015 Results on 4 February 2016

#### LUNG CANCER

| Name          | Phase | Line of treatment | Population                   | Design                | Timeline           | Status     |
|---------------|-------|-------------------|------------------------------|-----------------------|--------------------|------------|
| Early disease |       |                   |                              |                       |                    |            |
| Monotherapy   |       |                   |                              |                       |                    |            |
| ADJUVANT III  |       | N/A               | Stage Ib-IIIa NSCLC          | durvalumab vs placebo | Data expected 2020 | Recruiting |
| PACIFIC III   |       | N/A               | Stage III unresectable NSCLC | durvalumab vs placebo | Data expected 2017 | Recruiting |

## Advanced/metastatic disease

## Monotherapy

|             |          |                  |                         |                |   |
|-------------|----------|------------------|-------------------------|----------------|---|
| ATLANTIC II | 3rd line | PD-L1 pos. NSCLC | durvalumab (single arm) | Full data 2016 | - |
|-------------|----------|------------------|-------------------------|----------------|---|

## Combination therapy

|             |          |                      |                                                                                                   |                    |                                                                                                                |
|-------------|----------|----------------------|---------------------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------------------------------|
| ARCTIC III  | 3rd line | NSCLC                | durvalumab vs SoC (PD-L1 pos.) or durvalumab vs tremelimumab vs durva + treme vs SoC (PD-L1 neg.) | Data expected 2017 | Recruiting                                                                                                     |
| MYSTIC III  | 1st line | NSCLC (PFS endpoint) | durvalumab vs durva + treme vs SoC                                                                | Data expected 2017 | First patient dosed                                                                                            |
| NEPTUNE III | 1st line | NSCLC (OS endpoint)  | durva + treme vs SoC                                                                              | Data expected 2018 | Awaiting first patient dosed                                                                                   |
| - III       | 1st line | NSCLC                | durvalumab + chemotherapy +/- tremelimumab                                                        |                    | In preparation                                                                                                 |
| CAURAL III  | 2nd line | T790M+ NSCLC         | osimertinib vs osimertinib + durvalumab                                                           | Data expected 2018 | Initiated enrolment; currently on partial clinical hold to characterise incidence of interstitial lung disease |

## METASTATIC HEAD AND NECK CANCER

| Name                | Phase | Line of treatment | Population       | Design                                      | Timelines             | Status                                                      |
|---------------------|-------|-------------------|------------------|---------------------------------------------|-----------------------|-------------------------------------------------------------|
| Monotherapy         |       |                   |                  |                                             |                       |                                                             |
| HAWK                | II    | 2nd line          | PD-L1 pos. SCCHN | durvalumab (single arm)                     | Data expected H2 2016 | Recruiting<br>Indication granted FDA Fast Track designation |
| Combination therapy |       |                   |                  |                                             |                       |                                                             |
| CONDOR              | II    | 2nd line          | PD-L1 neg. SCCHN | durvalumab vs tremelimumab vs durva + treme | Data expected 2017    | Recruiting                                                  |
| EAGLE               | III   | 2nd line          | SCCHN            | durvalumab vs durva + treme vs SoC          | Data expected 2018    | In preparation                                              |
| KESTREL             | III   | 1st line          | SCCHN            | durvalumab vs durva + treme vs SoC          | Data expected 2018    | In preparation                                              |

## METASTATIC BLADDER CANCER

| Name   | Phase | Line of treatment | Population                                  | Design                             | Timelines          | Status              |
|--------|-------|-------------------|---------------------------------------------|------------------------------------|--------------------|---------------------|
| DANUBE | III   | 1st line          | Cisplatin chemo-therapy-eligible/ineligible | durvalumab vs durva + treme vs SoC | Data expected 2018 | First patient dosed |

## OTHER TUMOUR TYPES

## Edgar Filing: ASTRAZENECA PLC - Form 6-K

| Name | Phase | Line of treatment | Indication                      | Design                                            | Timelines Status  |
|------|-------|-------------------|---------------------------------|---------------------------------------------------|-------------------|
| -    | II    | 2nd/<br>3rd line  | Metastatic gastric cancer       | durvalumab vs<br>tremelimumab vs durva +<br>treme | In<br>preparation |
| -    | II    | 2nd line          | Unresect-able liver<br>cancer   | durvalumab vs<br>tremelimumab vs durva +<br>treme | In<br>preparation |
| ALPS | II    | 2nd line          | Metastatic pancreatic<br>cancer | durva + treme (single arm)                        | In<br>preparation |

SoC = Standard of Care, PFS = Progression Free Survival, OS = Overall Survival

### About durvalumab (MEDI4736)

Durvalumab is an investigational human monoclonal antibody directed against PD-L1. Signals from PD-L1 help tumours avoid detection by the immune system. Durvalumab blocks these signals, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer. Durvalumab is being investigated in an extensive clinical trial programme, as monotherapy or in combination with tremelimumab, in NSCLC, head and neck, gastric, pancreatic, bladder and blood cancers.

### About the ATLANTIC trial

ATLANTIC is a Phase II, non-comparative, open-label, multi-centre, international trial of durvalumab in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen.

### About AstraZeneca in Oncology

Oncology is a therapy area in which AstraZeneca has deep-rooted heritage. It will be potentially transformational for the company's future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we are aiming to bring six new cancer medicines to patients.

Our broad pipeline of next-generation medicines is focused on four main disease areas – lung, ovarian, breast and haematological cancers. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.

### About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: [www.astrazeneca.com](http://www.astrazeneca.com)

## CONTACTS

### Media Enquiries

|                  |           |                  |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 20 7604 8030 |
| Neil Burrows     | UK/Global | +44 20 7604 8032 |
| Vanessa Rhodes   | UK/Global | +44 20 7604 8037 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                     |                     |                  |
|---------------------|---------------------|------------------|
| Karen Birmingham    | UK/Global           | +44 20 7604 8120 |
| Jacob Lund          | Sweden              | +46 8 553 260 20 |
| Michele Meixell     | US                  | +1 302 885 2677  |
| Investor Enquiries  |                     |                  |
| UK                  |                     |                  |
| Thomas Kudsk Larsen | Oncology            | +44 7818 524185  |
| Eugenia Litz        | RIA                 | +44 7884 735627  |
| Nick Stone          | CVMD                | +44 7717 618834  |
| Craig Marks         | Finance             | +44 7881 615764  |
| Christer Gruvris    | Consensus Forecasts | +44 7827 836825  |
| US                  |                     |                  |
| Lindsey Trickett    | Oncology, ING       | +1 240 543 7970  |
| Mitch Chan          | Oncology            | +1 240 477 3771  |
| Dial / Toll-Free    |                     | +1 866 381 7277  |

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal

18 December 2015

-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 18 December 2015

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary